European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Ulf Landmesser; M. John Chapman; Michel Farnier; Baris Gencer; Stephan Gielen; G. Kees Hovingh; Thomas F. Lüscher; David Sinning; Lale Tokgözoglu; Olov Wiklund; Jose Luis Zamorano; Fausto J. Pinto; Alberico L. Catapano

doi:10.1093/eurheartj/ehw480

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

Ulf Landmesser
, M. John Chapman
, Michel Farnier
, Baris Gencer
, Stephan Gielen
, G. Kees Hovingh
, Thomas F. Lüscher
, David Sinning
, Lale Tokgözoglu
, Olov Wiklund
, Jose Luis Zamorano
, Fausto J. Pinto
, Alberico L. Catapano

Research output: Contribution to journal › Article › Academic › peer-review

58 Downloads (Pure)

Original language	English
Pages (from-to)	2245-2255
Journal	European heart journal
Volume	38
Issue number	29
Early online date	2016
DOIs	https://doi.org/10.1093/eurheartj/ehw480
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1093/eurheartj/ehw480

European-society-of-cardiologyeuropean-atherosclerosis-society-task-force-consensus-statement-on-proprotein-convertase-.pdfFinal published version, 677 KBLicence: Taverne

Cite this

Landmesser, U., Chapman, M. J., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., Lüscher, T. F., Sinning, D., Tokgözoglu, L., Wiklund, O., Zamorano, J. L., Pinto, F. J., & Catapano, A. L. (2017). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European heart journal, 38(29), 2245-2255. https://doi.org/10.1093/eurheartj/ehw480

@article{bdbb5901ab0742279026fe0415f70f35,

title = "European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk",

author = "Ulf Landmesser and Chapman, \{M. John\} and Michel Farnier and Baris Gencer and Stephan Gielen and Hovingh, \{G. Kees\} and L{\"u}scher, \{Thomas F.\} and David Sinning and Lale Tokg{\"o}zoglu and Olov Wiklund and Zamorano, \{Jose Luis\} and Pinto, \{Fausto J.\} and Catapano, \{Alberico L.\}",

year = "2017",

doi = "10.1093/eurheartj/ehw480",

language = "English",

volume = "38",

pages = "2245--2255",

journal = "European heart journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "29",

}

Landmesser, U, Chapman, MJ, Farnier, M, Gencer, B, Gielen, S, Hovingh, GK, Lüscher, TF, Sinning, D, Tokgözoglu, L, Wiklund, O, Zamorano, JL, Pinto, FJ & Catapano, AL 2017, 'European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk', European heart journal, vol. 38, no. 29, pp. 2245-2255. https://doi.org/10.1093/eurheartj/ehw480

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. / Landmesser, Ulf; Chapman, M. John; Farnier, Michel et al.
In: European heart journal, Vol. 38, No. 29, 2017, p. 2245-2255.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk

AU - Landmesser, Ulf

AU - Chapman, M. John

AU - Farnier, Michel

AU - Gencer, Baris

AU - Gielen, Stephan

AU - Hovingh, G. Kees

AU - Lüscher, Thomas F.

AU - Sinning, David

AU - Tokgözoglu, Lale

AU - Wiklund, Olov

AU - Zamorano, Jose Luis

AU - Pinto, Fausto J.

AU - Catapano, Alberico L.

PY - 2017

Y1 - 2017

U2 - 10.1093/eurheartj/ehw480

DO - 10.1093/eurheartj/ehw480

M3 - Article

C2 - 27789571

SN - 0195-668X

VL - 38

SP - 2245

EP - 2255

JO - European heart journal

JF - European heart journal

IS - 29

ER -

Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European heart journal. 2017;38(29):2245-2255. Epub 2016. doi: 10.1093/eurheartj/ehw480